ASX 200 healthcare shares led the 11 market sectors last week with a 4.84% increase over the five trading days.
The S&P/ASX 200 Index (ASX: XJO) lifted 0.28% amid a US-Iran interim peace deal and oil prices dropping to pre-war levels.
The ASX 200 finished the week at 8,828.7 points.
It’s potentially significant that healthcare was out in front last week given the sector’s poor performance over the past 12 months.
The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 39% over 12 months and down 25% in the calendar year to date.
The healthcare index hit a 9-year low of 21,947.2 points on 3 June.
Samy Sriram, a market analyst at online investment platform, Stake, says healthcare companies have had many headwinds.
They include currency challenges for those reporting in US dollars; three interest rate rises in Australia; cost of living pressures; higher shipping costs; new caps on insurance payouts in some nations; higher labour costs; and regulatory uncertainty in the US.
However, markets are cyclical. At some point in a downturn, share prices fall to levels that offer too much value to ignore, and investors dive back in.
Does 3 June represent that pivot point?
ASX 200 healthcare shares have increased 13% since 3 June compared to just a 0.49% bump for the broader benchmark index.
Let’s review some individual company performances last week.
Healthcare shares led the ASX sectors last week
The CSL Ltd (ASX: CSL) share price ascended 8.19% to close at $116.32 on Friday.
Sigma Healthcare Ltd (ASX: SIG) shares rose 4.55% to $2.76 apiece.
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares dropped 2.17% to $31.53.
Pro Medicus Ltd (ASX: PME) shares lifted 5.37% to $172.80.
Resmed CDIÂ (ASX: RMD) shares fell 3.75% to $26.68.
Sonic Healthcare Ltd (ASX: SHL) shares eased 0.74% to $20.05.
The Ramsay Health Care Ltd (ASX: RHC) share price lifted 1.73% to $39.49.
The Cochlear Ltd (ASX: COH) share price shot 13.87% higher to $118.14.
Telix Pharmaceuticals Ltd (ASX: TLX) shares increased 6.62% to $14.50.
The Ansell Ltd (ASX: ANN) share price rose 2.46% to $29.99.
The EBOS Group Ltd ASX: EBO) share price fell 3.87% to $16.91.
Mesoblast Ltd (ASX: MSB) shares ripped 9.23% to $2.13 apiece.
Megastar ASX 200 healthcare share, 4DMedical Ltd (ASX: 4DX), rocketed 23.37% to $4.54.
4DMedical shares are up 1,716% over 12 months.
ASX 200 market sector snapshot
Here’s how the 11 market sectors stacked up last week, according to CommSec data.
Over the five trading days:
| S&P/ASX 200 market sector | Change last week |
| Healthcare (ASX: XHJ) | 4.84% |
| Financials (ASX: XFJ) | 1.69% |
| Information Technology (ASX: XIJ) | 0.99% |
| Consumer Discretionary (ASX: XDJ) | 0.51% |
| Consumer Staples (ASX: XSJ) | 0.15% |
| A-REITÂ (ASX: XPJ) | 0.02% |
| Industrials (ASX: XNJ) | (0.13%) |
| Materials (ASX: XMJ) | (0.46%) |
| Communication (ASX: XTJ) | (1.67%) |
| Utilities (ASX: XUJ) | (3.66%) |
| Energy (ASX: XEJ) | (7.33%) |
The post Healthcare shares led the ASX 200 last week. Is a sector comeback underway? appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right nowâ¦
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- If I invest $8,000 in CSL shares, how much passive income will I receive in 2027?
- New to investing? 3 ASX shares to set and forget until 2036
- How to build a $1 million ASX share portfolio for retirement
- The bull and bear case for CSL shares
- 5 ASX 200 shares I would buy if I were starting from scratch
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Ansell, CSL, Cochlear, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.